Matterport expands Matterport Capture Services On-Demand to 22 U.S. cities 09:17 MTTR Matterport announced the expansion of Matterport Capture Services On-Demand to 22 new U.S. cities, increasing coverage to a total of 51 cities across the country. In addition, the company launched the service in four cities in the United Kingdom including London, Birmingham, Manchester and Leeds. As simple as ordering an Uber, Capture Services On-Demand lets companies within a 35-mile radius of these cities to quickly schedule a highly-trained Matterport Capture Technician to digitize any commercial or residential property or unique space. Once captured, the space is transformed into an immersive and precise 3D digital twin and delivered to the customer's account to access, manage and share the space more effectively than ever before.
GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
Funko, Inc. (FNKO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
$20.05+1.40 (+7.51%)<---------------
As of 10:31AM EDT. Market open.
Funko, Inc. (FNKO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
$20.05+1.40 (+7.51%)<---------------
As of 10:31AM EDT. Market open.
Is Mr Mizuzzo pulling a Slinger behind his StreetStrider?!
Tech is red... the Robo is up 1%!!!!
Short it Stoney! Kids in China are banned.
IPO lock-up 9/6
Its all bad.
ROBO to $65
Tile Shop>>>>> $7.77
Evolv Tech>>>> $7.77
Which one for the win Stoney?!
$EVLV will be $14 by spring!
The Tile Shop will be $5
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~
~ Full Study Enrollment Expected to be Completed by Mid-2022 ~
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in the second, higher-dose cohort in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease. These latest procedures follow a positive recommendation by the independent Data Safety Monitoring Board (DSMB) after reviewing available follow-up data from all participants in the trial. A total of 14 blinded administration procedures have now been completed, including four patients in the second dose cohort. In the study to date, eight patients have been treated with AMT-130, and six patients received imitation surgery.
In the fourth quarter of 2021, the Company expects the DSMB to review the 1-month safety data from the two most recently enrolled patients in the higher dose cohort, as well as the 3-month data from the first two patients. Upon receiving a positive recommendation from the DSMB, the Company will commence enrollment of the final 12 patients in the second dose cohort.
“We continue to be very pleased with the enrollment of this important study and look forward to having the trial fully enrolled by the middle of next year,” said David Cooper, M.D., vice president of clinical development at uniQure. “We also look forward to sharing preliminary imaging and biomarker data from initial patients in the U.S. clinical trial before the end of the year and initiating a separate open-label study of AMT-130 in Europe later this year.”
About the Phase I/II Clinical Program of AMT-130
The U.S. Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease will explore the safety, tolerability, and efficacy signals in 26 total patients with early manifest Huntington’s disease split into a 10 patient, low-dose cohort followed by a 16 patient, higher-dose cohort randomized to treatment with AMT-130 or an imitation (sham) surgery. The multi-center trial consists of a blinded 12-month core study period followed by unblinded long-term follow-up for five years. Patients will receive a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen). Additional details are available on www.clinicaltrials.gov (NCT04120493).
The European, open-label Phase Ib/II study of AMT-130 will enroll 15 patients with early manifest Huntington’s disease across two dose cohorts. Together with the U.S. study, the European study is intended to establish safety, proof of concept, and the optimal dose of AMT-130 to take forward into Phase III development or into a confirmatory study should an accelerated registration pathway be feasible.
AMT-130 is uniQure’s first clinical program focusing on the central nervous system (CNS) incorporating its proprietary miQURE™ platform.
About Huntington’s Disease
Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, and behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Despite the clear etiology of Huntington’s disease, there are no currently approved therapies to delay the onset or to slow the disease’s progression.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com
uniQure Forward-Looking Statements
~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~
~ Full Study Enrollment Expected to be Completed by Mid-2022 ~
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in the second, higher-dose cohort in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease. These latest procedures follow a positive recommendation by the independent Data Safety Monitoring Board (DSMB) after reviewing available follow-up data from all participants in the trial. A total of 14 blinded administration procedures have now been completed, including four patients in the second dose cohort. In the study to date, eight patients have been treated with AMT-130, and six patients received imitation surgery.
In the fourth quarter of 2021, the Company expects the DSMB to review the 1-month safety data from the two most recently enrolled patients in the higher dose cohort, as well as the 3-month data from the first two patients. Upon receiving a positive recommendation from the DSMB, the Company will commence enrollment of the final 12 patients in the second dose cohort.
“We continue to be very pleased with the enrollment of this important study and look forward to having the trial fully enrolled by the middle of next year,” said David Cooper, M.D., vice president of clinical development at uniQure. “We also look forward to sharing preliminary imaging and biomarker data from initial patients in the U.S. clinical trial before the end of the year and initiating a separate open-label study of AMT-130 in Europe later this year.”
About the Phase I/II Clinical Program of AMT-130
The U.S. Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease will explore the safety, tolerability, and efficacy signals in 26 total patients with early manifest Huntington’s disease split into a 10 patient, low-dose cohort followed by a 16 patient, higher-dose cohort randomized to treatment with AMT-130 or an imitation (sham) surgery. The multi-center trial consists of a blinded 12-month core study period followed by unblinded long-term follow-up for five years. Patients will receive a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen). Additional details are available on www.clinicaltrials.gov (NCT04120493).
The European, open-label Phase Ib/II study of AMT-130 will enroll 15 patients with early manifest Huntington’s disease across two dose cohorts. Together with the U.S. study, the European study is intended to establish safety, proof of concept, and the optimal dose of AMT-130 to take forward into Phase III development or into a confirmatory study should an accelerated registration pathway be feasible.
AMT-130 is uniQure’s first clinical program focusing on the central nervous system (CNS) incorporating its proprietary miQURE™ platform.
About Huntington’s Disease
Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, and behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Despite the clear etiology of Huntington’s disease, there are no currently approved therapies to delay the onset or to slow the disease’s progression.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com
uniQure Forward-Looking Statements
QURE Jan $50 calls have an open interest of 18.2K contracts.
Hmmmmm.
No volume to speak of on any strikes/expirations today though.
edit...
someone did a June $30/$40 spread.
Risk $2.25 to make $10
Pretty good trade really.
Only ten contracts, obviously not a whale, still looks like a good trade though.
Hmmmmm.
No volume to speak of on any strikes/expirations today though.
edit...
someone did a June $30/$40 spread.
Risk $2.25 to make $10
Pretty good trade really.
Only ten contracts, obviously not a whale, still looks like a good trade though.
Last edited:
Stumbled across this thread last week. Reminds me of the My Longshot is thread we had going years ago. Any hoo, I bought some EVLV and ELYS. ELYS making a nice run today on some good news.
What's up Stoney? Long time to see
What's up Stoney? Long time to see
geez what happened
Elys Game Technology Corp
NASDAQ: ELYS
6.20 USD +1.57 (33.91%)today
Aug 31, 11:45 AM EDT